Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Annal Hepatol. 2024;29(1): 101133. https://doi.org/10.1016/j.aohep.2023.101133

Article  Google Scholar 

Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2024;78(6):1966–1986. https://doi.org/10.1097/HEP.0000000000000520

Article  Google Scholar 

Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022;7(9):851–861. https://doi.org/10.1016/S2468-1253(22)00165-0

Article  CAS  PubMed  Google Scholar 

Le MH, Le DM, Baez TC, Wu Y, Ito T, Lee EY, et al. Global incidence of non-alcoholic fatty liver disease: a systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol. 2023;79(2):287–295. https://doi.org/10.1016/j.jhep.2023.03.040

Article  PubMed  Google Scholar 

Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–922. https://doi.org/10.1038/s41591-018-0104-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. Hepatology (Baltimore, MD). 2017;65(1):350–362. https://doi.org/10.1002/hep.28709

Article  PubMed  Google Scholar 

Alexander M, Loomis AK, Fairburn-Beech J, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, et al. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease. BMC Med. 2018;16(1):130. https://doi.org/10.1186/s12916-018-1103-x

Article  PubMed  PubMed Central  Google Scholar 

Tobari M, Hashimoto E, Taniai M, Ikarashi Y, Kodama K, Kogiso T, et al. Characteristics of non-alcoholic steatohepatitis among lean patients in Japan: not uncommon and not always benign. J Gastroenterol Hepatol. 2019;34:1404–1410. https://doi.org/10.1111/jgh.14585

Article  CAS  PubMed  Google Scholar 

Allen AM, Therneau TM, Larson JJ, Coward A, Somers VK, Kamath PS. Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: a 20 year-community study. Hepatology (Baltimore, MD). 2018;67(5):1726–1736. https://doi.org/10.1002/hep.29546

Article  CAS  PubMed  PubMed Central  Google Scholar 

Machado MV, Diehl AM. Pathogenesis of nonalcoholic steatohepatitis. Gastroenterology. 2016;150(8):1769–1777. https://doi.org/10.1053/j.gastro.2016.02.066

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zelber-Sagi S, Godos J, Salomone F. Lifestyle changes for the treatment of nonalcoholic fatty liver disease: a review of observational studies and intervention trials. Ther Adv Gastroenterol. 2016;9(3):392–407. https://doi.org/10.1177/1756283X16638830

Article  CAS  PubMed  PubMed Central  Google Scholar 

Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. N Engl J Med. 2024;390(6):497–509. https://doi.org/10.1056/NEJMoa2309000

Article  PubMed  Google Scholar 

US Food and Drug Administration. FDA approves first treatment for patients with liver scarring due to fatty liver disease. March 14, 2024. Accessed January 5, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease

Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. New Eng J Med. 2022;387(3):205–216. https://doi.org/10.1056/NEJMoa2206038

Article  CAS  PubMed  Google Scholar 

Hu W, Gong W, Yang F, Cheng R, Zhang G, Gan L, et al. Dual GIP and GLP-1 receptor agonist tirzepatide alleviates hepatic steatosis and modulates gut microbiota and bile acid metabolism in diabetic mice. Int Immunopharmacol. 2025;147: 113937. https://doi.org/10.1016/j.intimp.2024.113937

Article  CAS  PubMed  Google Scholar 

Tall Bull S, Nuffer W, Trujillo JM. Tirzepatide: a novel, first-in-class, dual GIP/GLP-1 receptor agonist. J Diabetes Complications. 2022;36(12): 108332. https://doi.org/10.1016/j.jdiacomp.2022.108332

Article  CAS  PubMed  Google Scholar 

Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, et al. Tirzepatide for metabolic dysfunction-associated steatohepatitis with liver fibrosis. N Engl J Med. 2024;391(4):299–310. https://doi.org/10.1056/NEJMoa2401943

Article  CAS  PubMed  Google Scholar 

Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, et al. The natural history of advanced fibrosis due to nonalcoholic steatohepatitis: data from the simtuzumab trials. Hepatology (Baltimore, MD). 2019;70(6):1913–1927. https://doi.org/10.1002/hep.30664

Article  CAS  PubMed  Google Scholar 

Ludwig RJ, Anson M, Zirpel H, Thaci D, Olbrich H, Bieber K, et al. A comprehensive review of methodologies and application to use the real-world data and analytics platform TriNetX. Front Pharmacol. 2025;16:1516126. https://doi.org/10.3389/fphar.2025.1516126

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. https://doi.org/10.1056/NEJMoa1504720

Article  CAS  PubMed  Google Scholar 

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. New Eng J Med. 2019;381(21):1995–2008

Article  CAS  PubMed  Google Scholar 

Khalil I, Hossain MI, Akter M. Evaluating the comparative effectiveness of sodium-glucose transporter 2 inhibitors (SGLT-2i) on liver enzymes in patients with nonalcoholic fatty liver disease: a comprehensive systematic review and bayesian network meta-analysis of randomized controlled trials. AACE Endocrinol Diabetes. 2025;12(4):328–338. https://doi.org/10.1016/j.aed.2025.08.007

Article  CAS  PubMed  PubMed Central  Google Scholar 

TriNetX Global Health Research Network. Platform overview and compliance: HIPAA/GDPR Adherence. Cambridge, MA: TriNetX; 2026. https://www.trinetx.com/ Accessed: 5 Jan 2026

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (London, England). 2007;370(9596):1453–1457. https://doi.org/10.1016/S0140-6736(07)61602-X

Article  Google Scholar 

Kamrul-Hasan ABM, Chatterjee S, Ashraf H, Nagendra L, Dutta D, Pappachan JM. Cardiovascular outcomes in adults with type 2 diabetes treated with tirzepatide: a systematic review and meta-analysis of real-world studies. Endocr Pract. 2025. https://doi.org/10.1016/j.eprac.2025.11.010

Article  PubMed  Google Scholar 

Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z, et al. Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol. 2011;54(6):1214–1223. https://doi.org/10.1016/j.jhep.2010.09.032

Article  CAS  PubMed  Google Scholar 

Liuzzo G, Patrono C. Dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonism for substantial body weight reduction in obese subjects. Eur Heart J. 2022;43(35):3288–3289. https://doi.org/10.1093/eurheartj/ehac384

Article  PubMed  Google Scholar 

Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018;15(2):111–128. https://doi.org/10.1038/nrgastro.2017.119

Article  CAS  PubMed  Google Scholar 

Schwabe RF, Tabas I, Pajvani UB. Mechanisms of fibrosis development in nonalcoholic steatohepatitis. Gastroenterology. 2020;158(7):1913–1928. https://doi.org/10.1053/j.gastro.2019.11.311

Article  CAS  PubMed  PubMed Central